1.2 Carbohydrates & Lipids

Carbohydrates and Lipids

Carbohydrates and lipids serve as the foundational energy substrates and structural components of the human body. Dysregulation of their metabolic pathways leads to some of the most prevalent chronic diseases, particularly Diabetes Mellitus and cardiovascular disease. Accurate measurement of glucose, cholesterol, and their related biomarkers is a cornerstone of the clinical chemistry laboratory.

Carbohydrate Metabolism and Regulation

Glucose is a monosaccharide and the primary energy source for cellular metabolism, especially for the brain, which relies almost entirely on glucose for ATP production. Blood glucose levels are maintained within a tight fasting physiological range of 70-99 mg/dL through a complex hormonal balancing act.

Hormonal Regulation

• Insulin: Synthesized by the beta cells of the Islets of Langerhans in the pancreas. Insulin is the only hypoglycemic hormone (it decreases blood glucose). Upon binding to its cellular receptors, it promotes the translocation of GLUT4 transporters to the cell membrane in muscle and adipose tissue, facilitating glucose uptake. It also stimulates glycogenesis (storing glucose as glycogen in the liver and muscle) and lipogenesis, while inhibiting gluconeogenesis.
• Glucagon: Synthesized by the alpha cells of the pancreas, glucagon is the primary counter-regulatory hormone. When blood glucose drops, glucagon is released and travels to the liver, where it rapidly stimulates glycogenolysis (breakdown of glycogen to free glucose) and gluconeogenesis (creation of new glucose from amino acids and glycerol).
• Epinephrine: Produced by the adrenal medulla during the "fight or flight" stress response, epinephrine causes an immediate and rapid release of glucose from liver glycogen stores.
• Cortisol and Growth Hormone: These hormones antagonize the action of insulin. Cortisol, produced by the adrenal cortex, promotes gluconeogenesis and decreases cellular glucose uptake. Chronic elevations in these hormones (e.g., Cushing's syndrome, Acromegaly) frequently lead to hyperglycemia.

Diabetes Mellitus

Diabetes Mellitus (DM) is a group of metabolic disorders characterized by persistent hyperglycemia resulting from defects in insulin secretion, insulin action, or both.

• Type 1 Diabetes Mellitus (T1DM): An autoimmune condition characterized by the destruction of pancreatic beta cells, leading to absolute insulin deficiency. Patients rely on exogenous insulin. Because insulin is entirely absent, lipolysis is uninhibited, leading to the rapid generation of ketone bodies (acetoacetate, beta-hydroxybutyrate, and acetone) and a high risk of Diabetic Ketoacidosis (DKA).
• Type 2 Diabetes Mellitus (T2DM): The most common form, characterized by peripheral insulin resistance followed by a progressive decline in insulin secretion. It is strongly associated with obesity, a sedentary lifestyle, and metabolic syndrome. These patients are more prone to Hyperosmolar Hyperglycemic State (HHS) rather than DKA.
• Gestational Diabetes Mellitus (GDM): Glucose intolerance with onset or first recognition during pregnancy, driven by placental hormones that cause insulin resistance.

Diagnostic Criteria (American Diabetes Association): A diagnosis of diabetes can be made if any one of the following criteria is met (usually confirmed by repeat testing on a subsequent day):

1. Fasting Plasma Glucose (FPG): ≥ 126 mg/dL (fasting defined as no caloric intake for at least 8 hours).
2. 2-hour Oral Glucose Tolerance Test (OGTT): ≥ 200 mg/dL following a 75g oral glucose load.
3. Hemoglobin A1c (HbA1c): ≥ 6.5%.
4. Random Plasma Glucose: ≥ 200 mg/dL in a patient exhibiting classic symptoms of hyperglycemia (polyuria, polydipsia, unexplained weight loss).

Analytical Methods for Glucose and A1c

1. Hexokinase Method: This is the accepted reference method for glucose determination due to its high specificity. It is a coupled enzymatic reaction:
   • Step 1: Glucose + ATP → (Hexokinase) → Glucose-6-Phosphate (G6P) + ADP.
   • Step 2: G6P + NADP+ → (Glucose-6-Phosphate Dehydrogenase) → 6-Phosphogluconate + NADPH + H+.
   • Detection: The reaction is monitored spectrophotometrically at 340 nm by measuring the increase in absorbance as NADP+ is reduced to NADPH. This method is highly accurate and free from most common interferences.
2. Glucose Oxidase Method:
   • Step 1: Glucose + O2 + H2O → (Glucose Oxidase) → Gluconic Acid + H2O2.
   • Step 2 (Trinder Reaction): H2O2 + Chromogen (e.g., 4-aminoantipyrine) → (Peroxidase) → Colored oxidized complex + H2O.
   • Interferences: Ascorbic acid, uric acid, and bilirubin are reducing substances that can compete with the chromogen for H2O2, potentially causing falsely decreased glucose results.
3. Hemoglobin A1c (Glycated Hemoglobin): HbA1c is formed by the non-enzymatic, irreversible attachment of glucose to the N-terminal valine of the beta chain of hemoglobin. The rate of formation is directly proportional to the plasma glucose concentration. Because red blood cells live for ~120 days, HbA1c reflects the average blood glucose over the preceding 2-3 months. Common analytical methods include ion-exchange HPLC, affinity chromatography, and immunoassays.

Lipid Metabolism

Lipids are hydrophobic molecules essential for cell membrane integrity, steroid hormone synthesis, and energy storage. To travel through the aqueous environment of the bloodstream, lipids must be packaged into water-soluble complexes called lipoproteins. Lipoproteins consist of a core of nonpolar lipids (triglycerides and cholesterol esters) surrounded by an amphipathic shell of phospholipids, free cholesterol, and apolipoproteins.

Major Lipoprotein Classes

Clinical Lipid Profiles

A standard lipid panel assesses cardiovascular disease risk and includes Total Cholesterol (TC), Triglycerides (TG), HDL Cholesterol, and calculated LDL Cholesterol. Patients should fast for 10-12 hours before a lipid panel to ensure the complete clearance of chylomicrons, which would otherwise falsely elevate the triglyceride measurement.

Desirable Reference Ranges:

• Total Cholesterol: < 200 mg/dL
• Triglycerides: < 150 mg/dL
• HDL Cholesterol: ≥ 40 mg/dL (males) / ≥ 50 mg/dL (females)
• LDL Cholesterol: < 100 mg/dL

The Friedewald Equation for LDL

In most clinical laboratories, LDL cholesterol is not measured directly due to cost and complexity. Instead, it is estimated using the Friedewald equation:

LDL = Total Cholesterol - (HDL + (Triglycerides / 5))

Rationale: The term (Triglycerides / 5) provides an estimate of VLDL cholesterol content, based on the assumption that the ratio of triglycerides to cholesterol in VLDL particles is roughly 5:1. Crucial Limitation: The Friedewald equation becomes completely invalid if the patient's Triglyceride level exceeds 400 mg/dL. In such cases, the VLDL estimate is highly inaccurate, and a direct LDL measurement method must be performed.

Analytical Methods for Lipids

• Cholesterol Measurement: Total cholesterol is quantified using a multi-step enzymatic reaction sequence: Cholesterol Esterase (hydrolyzes esters to free cholesterol) → Cholesterol Oxidase (oxidizes cholesterol to produce H2O2) → Peroxidase (Trinder reaction to form a colored dye).
• Triglyceride Measurement: Measured enzymatically by first hydrolyzing triglycerides into glycerol and free fatty acids using a bacterial Lipase. The glycerol is then phosphorylated by Glycerol Kinase, oxidized by Glycerol Phosphate Oxidase to produce H2O2, and measured via a peroxidase reaction.